Autologous Fat and its Derivatives in Clinical Practice: A Narrative Review of Global Regulatory Frameworks

Abstract

Autologous fat grafting has transitioned from traditional reconstructive soft-tissue filling to an expansive platform for reconstructive surgery, regenerative medicine, and point-of-care cellular therapy. This clinical evolution has driven the development of various adipose-derived derivatives, including micro-fat, nano-fat, micro-fragmented adipose tissue (MFAT), and enzymatically isolated stromal vascular fraction (SVF). However, clinical translation is complex due to a highly fragmented global regulatory landscape.
Central to international oversight are the thresholds of "minimal manipulation" and "homologous use". Crossing these thresholds, such as utilizing enzymatic digestion to isolate SVF or applying adipose tissue for non-homologous indications like joint regeneration, generally triggers classification as a drug, biologic, or Advanced Therapy Medicinal Product (ATMP). Such classifications demand stringent clinical trial validation, Good Manufacturing Practice (GMP) compliance, and pre-market approvals under frameworks like the US FDA and EU EMA. Conversely, jurisdictions like Australia and Japan offer alternative pathways, including hospital-based exclusions or tiered clinical practice oversight under the Act on the Safety of Regenerative Medicine (ASRM). Evolving guidelines under India's CDSCO similarly categorise enzymatic processing as substantial manipulation, defining the final output as a "New Drug".
This narrative review compares these regulatory pathways, highlighting how jurisdictional variation drives a geographic split in clinical innovation and underscores the necessity of regulatory literacy for clinicians and device developers alike.